Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.40 |
| ▸ | CASR | P41180 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28223834 | 0.75 | CASR (0.43) | ADRA2AADRA2BADRA2CCASRALDH1A1 | |
| SCHEMBL7705711 | 0.74 | ALDH1A1 (0.48) | SLC6A4CASRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5610407 | 0.73 | ALDH1A1 (0.47) | SLC6A4ADRA2AADRA2BADRA2CCASR | |
| SCHEMBL6014505 | 0.73 | ALDH1A1 (0.47) | SLC6A4CASRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL820090 | 0.73 | ALDH1A1 (0.47) | SLC6A4CASRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL5610397 | 0.73 | ALDH1A1 (0.47) | SLC6A4ADRA2AADRA2BADRA2CCASR | |
| SCHEMBL536861 | 0.73 | ALDH1A1 (0.47) | SLC6A4ADRA2AADRA2BADRA2CCASR | |
| SCHEMBL820089 | 0.73 | ALDH1A1 (0.47) | SLC6A4CASRALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL22897010 | 0.71 | SLC6A4 (0.40) | SLC6A4CASR | |
| SCHEMBL2125548 | 0.71 | ALDH1A1 (0.46) | SLC6A4CASRALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2019-01-01 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166215-B2 | Substituted bicyclic compounds as bromodomain inhibitors | BRD4, BRD3, BRD2 | SLC6A4 4729/4885ADRA2A 3550/4885ADRA2B 2921/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | SLC6A4 4730/4885ADRA2A 3317/4885ADRA2B 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.